HK Stock Market Move | REMEGEN (09995) rose over 5% in the morning session, achieving substantial profits for the first time on a medium-term basis, with significant contributions from overseas licensing.

REMEGEN (09995) rose over 5% in the morning session and, as of the time of writing, is up 5.6% at HKD 83.95, with a trading volume of HKD 298 million. In terms of news, REMEGEN has announced a positive profit forecast, estimating that its revenue for the first half of the year will be approximately RMB 5.85 billion, a year-on-year increase of more than 430%; it anticipates a net profit attributable to shareholders of RMB 4.7 billion, with a non-recurring net profit of about RMB 4.3 billion. Comparatively, the company's revenue forecast for the first half has already surpassed the total revenue level for the entire year of 2025, and its profit scale is significantly higher than the net profit attributable to shareholders for the entire year of 2025, marking the company's first substantial profit since its listing in the interim report context. The announcement stated that the growth in performance is mainly due to the continuous increase in domestic sales revenue from its core commercialized products, Taltirexip and Vedolizumab; secondly, the exclusive licensing agreement for RC148 with AbbVie outside the Greater China region has brought in significant technical licensing revenue, becoming the core incremental source of profit for this period. It is reported that in January of this year, REMEGEN signed an overseas licensing agreement for RC148 (PD-1/VEGF dual antibody) with AbbVie, with a total transaction amount that could reach up to USD 5.6 billion.